Trial: 201803113

A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors



Principal Investigator

Ansstas, George

Disease Site

Anus; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Melanoma, Skin; Other Digestive Organ; Other Respiratory and Intrathoracic Organs; Pancreas; Rectum; Small Intestine; Stomach; Thyroid; Urinary Bladder

Learn more about this study at: